160 related articles for article (PubMed ID: 35704937)
1. Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
Jackson EB; Hotte SJ
Can Urol Assoc J; 2022 Nov; 16(11):E516-E522. PubMed ID: 35704937
[TBL] [Abstract][Full Text] [Related]
2. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.
Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW
Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796
[TBL] [Abstract][Full Text] [Related]
3. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
4. Determinants of the Cancer Drug Funding Process in Canada.
Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
[TBL] [Abstract][Full Text] [Related]
5. Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report.
Naipaul R; Marques C; Ng J; Barbour S; Lo C; Hildebrand AM; Siu V; Prasad B; Laurin LP; Wazny LD; Armstrong S; Tran J; Sheffield M; Jauhal A; Hladunewich MA
Can J Kidney Health Dis; 2023; 10():20543581231190227. PubMed ID: 37581108
[TBL] [Abstract][Full Text] [Related]
6. Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces.
Woon DTS; Chandrasekar T; Aaron L; Basappa NS; Chi KN; Conter HJ; Gotto G; Hotte SJ; Malone S; Saad F; Shayegan B; Park-Wyllie L; Hamilton RJ
Can Urol Assoc J; 2018 Oct; 12(10):328-336. PubMed ID: 29688882
[TBL] [Abstract][Full Text] [Related]
7. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
[TBL] [Abstract][Full Text] [Related]
8. The timing of drug funding announcements relative to elections: a case study involving dementia medications.
Gill SS; Gupta N; Bell CM; Rochon PA; Austin PC; Laupacis A
PLoS One; 2013; 8(2):e56921. PubMed ID: 23460820
[TBL] [Abstract][Full Text] [Related]
9. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
10. Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada.
Gotfrit J; Shin JJW; Mallick R; Stewart DJ; Wheatley-Price P
Oncologist; 2020 Jan; 25(1):e130-e137. PubMed ID: 31506392
[TBL] [Abstract][Full Text] [Related]
11. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
[TBL] [Abstract][Full Text] [Related]
12. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
[TBL] [Abstract][Full Text] [Related]
13. Understanding the reasons for provincial discordance in cancer drug funding-a survey of policymakers.
Srikanthan A; Penner N; Chan KKW; Sabharwal M; Grill A
Curr Oncol; 2018 Aug; 25(4):257-261. PubMed ID: 30111966
[TBL] [Abstract][Full Text] [Related]
14. FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment.
Ho C; Lim HJ; Regier DA
Curr Oncol; 2022 Jan; 29(2):402-410. PubMed ID: 35200536
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis.
Santoni M; Rizzo A; Mollica V; Rosellini M; Marchetti A; Fragomeno B; Battelli N; Massari F
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):45-51. PubMed ID: 34058953
[TBL] [Abstract][Full Text] [Related]
16. [Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].
Miller K; Bergmann L; Doehn C; Gschwend J; Keilholz U
Aktuelle Urol; 2017 Feb; 48(1):72-78. PubMed ID: 28403496
[TBL] [Abstract][Full Text] [Related]
17. [Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma].
Miller K; Bergmann L; Doehn C; Grünwald V; Gschwend JE; Ivanyi P; Keilholz U; Kuczyk MA
Aktuelle Urol; 2020 Dec; 51(6):572-581. PubMed ID: 33027832
[TBL] [Abstract][Full Text] [Related]
18. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
19. Impact of Oncology Drug Review Times on Public Funding Recommendations.
Hussain M; Wong C; Taguedong E; Verma S; Mahsin M; Karim S; Lee-Ying R; Ezeife DA
Curr Oncol; 2023 Aug; 30(8):7706-7712. PubMed ID: 37623039
[TBL] [Abstract][Full Text] [Related]
20. Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration.
Ezeife DA; Truong TH; Heng DY; Bourque S; Welch SA; Tang PA
Cancer; 2015 May; 121(10):1688-93. PubMed ID: 25604014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]